Drug intelligence / Profile preview

CTN-012

Development stage: Preclinical
Lead developer: Centenaire Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CTN-012 is a monoclonal antibody drug candidate developed by Centenaire Biosciences. It functions as an antagonist of fibroblast growth factor receptor 3 (FGFR3), targeting this receptor to inhibit its activity. FGFR3 is implicated in the development and progression of certain cancers, particularly bladder cancer. By blocking FGFR3 signaling, CTN-012 aims to disrupt tumor cell proliferation and survival pathways associated with neoplasms and urogenital diseases. As of May 2025, the drug remains in preclinical development for bladder cancer[1].

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on CTN-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTN-012.

Explore the full profile